Loading...
Emergent BioSolutions Q1 2025 Earnings Report
Emergent BioSolutions reported a decrease in total revenues but a significant increase in net income for the first quarter of 2025.
Key Takeaways
Emergent BioSolutions reported a 26% decrease in total revenues to $222.2 million for Q1 2025 compared to Q1 2024, but net income surged by 656% to $68.0 million. The company's gross margin expanded to 50%, and adjusted EBITDA increased by 16% to $77.6 million, demonstrating improved profitability despite lower sales.
Total revenues decreased by 26% to $222.2 million in Q1 2025 compared to Q1 2024.
Net income increased by 656% to $68.0 million in Q1 2025 compared to Q1 2024.
Adjusted EBITDA increased by 16% to $77.6 million in Q1 2025 compared to Q1 2024.
Gross Margin % expanded to 50% and Adjusted Gross Margin % to 58% in Q1 2025.
Emergent BioSolutions
Emergent BioSolutions
Emergent BioSolutions Revenue by Segment
Revenue by Segment
NARCAN Nasal Spray Revenue
CapyFin.comAnthrax MCM Revenue
CapyFin.comSmallpox MCM Revenue
CapyFin.comOther Products Revenue
CapyFin.comContracts and Grants Revenue
CapyFin.comServices Revenue
CapyFin.com Forward Guidance
Emergent BioSolutions reaffirmed its full-year 2025 guidance, with total revenues expected to remain between $750 million and $850 million. The company anticipates increased net income and maintains its outlook for adjusted net income, adjusted EBITDA, and adjusted gross margin percentage.
Positive Outlook
- Total revenues guidance reaffirmed at $750-$850 million for FY 2025.
- Net income guidance increased to $20-$70 million for FY 2025.
- Adjusted net income guidance reaffirmed at $20-$70 million for FY 2025.
- Adjusted EBITDA guidance reaffirmed at $150-$200 million for FY 2025.
- Adjusted gross margin % guidance reaffirmed at 48%-51% for FY 2025.
Challenges Ahead
- No specific negative adjustments or revised downward forecasts were provided in the guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income